Kindred Biosciences Announces Third Quarter 2020 Financial Results
SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets,today announced financial results for the third quarter ended September 30, 2020 and provided updates on its programs.
- SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets,today announced financial results for the third quarter ended September 30, 2020 and provided updates on its programs.
- For the third quarter of 2020, KindredBio reported net revenues of $1.0 million and a net loss of $12.2 million, or $0.31 per share.
- On September 16, 2020, KindredBio reported positive results from its pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine parvovirus (CPV).
- The company recorded royalty revenue of $255,000 in the third quarter and $413,000 for the first nine months of 2020.